Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 16/20 | 0.54 |
| ▸ | NPY1R | P25929 | 10/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.54 |
| ▸ | NPY2R | P49146 | 6/20 | 0.54 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.48 |
| ▸ | NMT2 | O60551 | 1/20 | 0.47 |
| ▸ | NMT1 | P30419 | 1/20 | 0.47 |
| ▸ | TFPI | P10646 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16299127 | 0.92 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2RNMT2 | |
| SCHEMBL10168621 | 0.92 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2RNMT2 | |
| SCHEMBL10169061 | 0.92 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2RNMT2 | |
| SCHEMBL10169230 | 0.92 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2RNMT2 | |
| SCHEMBL15185942 | 0.91 | NPY4R (0.56) | NPY4RNPY1RNPY5RNPY2RSIRT6 | |
| SCHEMBL16507920 | 0.90 | FURIN (0.51) | SIRT6SIRT1NMT2NMT1 | |
| SCHEMBL19558265 | 0.89 | FURIN (0.55) | NPY4RNPY1RNPY5RNPY2RSIRT6 | |
| SCHEMBL15896438 | 0.89 | FURIN (0.55) | NPY4RNPY1RNPY5RNPY2RSIRT6 | |
| SCHEMBL10168319 | 0.89 | NPY4R (0.53) | NPY4RNPY1RNPY5RNPY2RNMT2 | |
| SCHEMBL10168318 | 0.88 | SIRT6 (0.46) | NPY4RNPY1RNPY5RNPY2RSIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028888-A1 | APJ RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028888-A1 | APJ RECEPTOR COMPOUNDS | APLNR, AP1G1, AP2B1 | NPY4R 1574/4885NPY1R 1171/4885NPY5R 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.